

Kontrollgruppe. 5-FU unterdrückte die Fibronectinexpression ab Tag 15 signifikant besser als Genistein oder Suramin.

Unterschiede zwischen aktivierten und nicht-aktiviert Tenonfibroblastenpopulationen konnten mit statistischer Signifikanz lediglich in der Fibronectinexpression festgestellt werden. Diese Unterschiede wurden durch die medikamentöse Behandlung, unabhängig davon mit welchem Medikament sie erfolgte, unterdrückt.

Zusammenfassend hemmen sowohl Genistein als auch Suramin die einzelnen Funktionen des Tenonfibroblasten signifikant. Diese Hemmung erstreckt sich über einen mindestens vier Wochen dauernden Zeitraum. Genistein hat dabei in einzelnen Zellfunktionen zeitweise eine stärkere Wirkung als das etablierte 5-FU und ist in seiner Wirkung mit 5-FU vergleichbar. Suramin hatte einen schwächeren Effekt auf die Fibroblastenfunktionen als 5-FU.

## Kapitel 7: Bibliographie

1. **Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y.** (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. *J Biol Chem.* **262**, 5592-5.
2. **Akman A., Bilezikci B., Kucukerdonmez C., Demirhan B., Aydin P.** (2003) Suramin modulates wound healing of rabbit conjunctiva after trabeculectomy: comparison with mitomycin C. *Curr Eye Res.* **26**, 37-43.
3. **Atreides S.P., Skuta G.L., Reynolds A.C.** (2004) Wound healing modulation in glaucoma filtering surgery. *Int. Ophthalmol. Clin.* **44**, 61-106.
4. **Azuma Y., Onishi Y., Sato Y., Kizaki H.** (1995) Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. *J Biochem* **118**, 312-8.
5. **Bastian S.E., Dunbar A.J., Priebe I.K., Owens P.C., Goddard C.** (2001) Measurement of betacellulin levels in bovine serum, colostrum and milk. *J Endocrinol.* **168**, 203-12.

6. **Bian Z.M., Elnér S.G., Elnér V.M.** (2007) Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. *Exp Eye Res.* **84**, 812-22.
7. **Bowen-Pope D.F., Hart C.E., Seifert R.A.** (1989) Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. *J Biol Chem.* **264**, 2502-8.
8. **Bradshaw R.A., Cavanaugh K.P.** (1990) Isolation and Characterization of Growth Factors , in Roberts A.B., und Sporn M.B. (Hrsg.) *Peptide Growth Factors and their Receptors I* . Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong , 17-36
9. **Browning A., Alibhai A., McIntosh R., Rotchford A., Bhan A., Amoaku W.M.** (2005) Effect of diabetes mellitus and hyperglycemia on the proliferation of human Tenon's capsule fibroblasts: implications for wound healing after glaucoma drainage surgery. *Wound Repair Regen.* **13**, 295-302.
10. **Cairns J.E.** (1968) Trabeculectomy – Preliminary report of a new method. *American Journal of Ophthalmology.* **66**, 673 - 679
11. **Cerra A., Mansfield K.J., Chamberlain C.G.** (2003) Exacerbation of TGF-beta induced cataract by FGF-2 in cultured rat lenses. *Mol Vis.* **9**, 689-700.
12. **Chamberlain J., Shah M., Ferguson M.W.** (1995) The effect of suramin on healing adult rodent dermal wounds. *J Anat.* **186**, 87-96.
13. **Chan Y.S., Li Y., Foster W., Horaguchi T., Somogyi G., Fu F.H., Huard J.** (2003) Antifibrotic effects of suramin in injured skeletal muscle after laceration. *J Appl Physiol.* **95**, 771-80.
14. **Chan Y.S., Li Y., Foster W., Fu F.H., Huard J.** (2005) The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. *Am J Sports Med.* **33**, 43-51.
15. **Chang L., Crowston J.G., Cordeiro M.F., Akbar A.N., Khaw P.T.** (2000) The role of the immune system in conjunctival wound healing after glaucoma surgery. *Surv Ophthalmol.* **45**, 49-68.
16. **Childs C.B., Proper J.A., Tucker R.F., Moses H.L.** (1982) Serum contains a plateled-derived transforming growth factor. *Proc Natl Acad Sci USA.* **79**, 5312-16.
17. **Chen C.A., Hwang J.C., Guh J.Y., Tsai J.C., Chen H.C.** (2006) TGF-beta1 and integrin synergistically facilitate the differentiation of rat podocytes by increasing alpha-smooth muscle actin expression. *Transl Res.* **148**, 134-41.
18. **Coffey R.J. Jr., Leof E.B., Shipley G.D., Moses H.L.** (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. *J Cell Physiol.* **132**, 143-8.

19. **Collignon N.J.** (2005) Wound healing after glaucoma surgery: how to manage it? *Bull Soc Belge Ophthalmol.* **295**, 55-9.
20. **Cordeiro M.F., Bhattacharya S.S., Schultz G.S., Khaw P.T.** (2000) TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. *Invest Ophthalmol Vis Sci.* **41**, 756-63.
21. **Cunliffe I.A., Rees R.C., Rennie I.G.** (1996) The effect of TGF-beta 1 and TGF beta 2 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. *Acta Ophthalmol Scand.* **74**, 31-5.
22. **Daniels J.T., Occleston N.L., Crowston J.G., Cordeiro M.F., Alexander R.A., Wilkins M., Porter R., Brown R., Khaw P.T.** (1998) Understanding and controlling the scarring response: the contribution of histology and microscopy. *Microsc Res Tech.* **42**, 317-33.
23. **Dean N.M., Kanemitsu M., Boynton A.L.** (1989) Effects of the tyrosine-kinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and rat liver T51B cells. *Biochem Biophys Res Commun.* **165**, 795-801.
24. **Denk P.O., Knorr M.** (1999) Serum-free cultivation of human Tenon's capsule fibroblasts. *Curr Eye Res.* **18**, 130-4.
25. **Denk P.O., Roth-Eichhorn S., Gressner A.M., Knorr M.** (2000) Cytokine regulation of hyaluronate production by human Tenon's capsule fibroblasts. *Curr Eye Res.* **20**, 77-80.
26. **Denk P.O., Hoppe J., Hoppe V., Knorr M.** (2003) Effect of growth factors on the activation of human Tenon's capsule fibroblasts. *Curr Eye Res.* **27**, 35-44.
27. **de Wecker L.** (1882) La cicatrice à filtration. *Annales d'oculistique* **87**, 133-143.
28. **Diestelhorst M., Khalili M.A., Krieglstein G.K.** (1999) Trabeculectomy: a retrospective follow-up of 700 eyes. *Int Ophthalmol.* **22**, 211-20.
29. **Dietlein T.S.** (2006) Glaukom im Alter – Barrieren für Aufklärung und Compliance *Ophthalmologe.* **103**, 755-8.
30. **Ellis D.G., Cheng Q., Lee D.A.** (1996) The effects of growth factors on Tenon's capsule fibroblasts in serum-free culture. *Curr Eye Res.* **15**, 27-35.
31. **Fautsch M.P., Howell K.G., Vrabel A.M., Charlesworth M.C., Muddiman D.C., Johnson D.H.** (2005) Primary trabecular meshwork cells incubated in human aqueous humor differ from cells incubated in serum supplements. *Invest Ophthalmol Vis Sci.* **46**, 2848-56.
32. **Foekens J.A., Sieuwerts A.M., Stuurman-Smeets E.M., Peters H.A., Klijn J.G.** (1992) Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. *Int. J. Cancer* **51**, 439 – 444

33. **Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J.** (2002) The definition and classification of glaucoma in prevalence surveys. *Br J Ophthalmol.* **86**, 238-42.
34. **Francis B.A., Du L.T., Najafi K., Murthy R., Kurumety U., Rao N., Minckler D.S.** (2005) Histopathologic features of conjunctival filtering blebs. *Arch Ophthalmol.* **123**, 166-70.
35. **Gong H., Tripathi R.C., Tripathi B.J.** (1996) Morphology of the aqueous outflow pathway. *Microsc Res Tech.* **33**, 336-67.
36. **Gressel M.G., Heuer D.K., Parrish R.K. 2nd.** (1984) Trabeculectomy in young patients. *Ophthalmology.* **91**, 1242-6.
37. **Gross R.L.** (1999) Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid. *Trans Am ophthalmol soc* **97**, 513-543
38. **Gu X., Seong G.J., Lee Y.G., Kay E.P.** (1996) Fibroblast growth factor 2 uses distinct signaling pathways for cell proliferation and cell shape changes in corneal endothelial cells. *Invest Ophthalmol Vis Sci.* **37**, 2326-34.
39. **Haq F., Trinkaus-Randall V.** (1998) Injury of stromal fibroblasts induces phosphorylation of focal adhesion proteins. *Curr Eye Res.* **17**, 512-23.
40. **Haugh J.M.** (2002) Localization of Receptor-Mediated Signal Transduction Pathways: The Inside Story. *Mol Interv.* **2**, 292-307.
41. **Hawker J.R. Jr., Granger H.J.** (1994) Tyrosine kinase inhibitors impair fibroblast growth factor signaling in coronary endothelial cells. *Am J Physiol.* **266**, 107-20.
42. **Honegger A., Humbel R.E.** (1986) Insulin-like growth factors I and II in fetal and adult bovine serum. Purification, primary structures, and immunological cross-reactivities. *J Biol Chem.* **261**, 569-75.
43. **Hoyng P.F., van Beek L.M.** (2000) Pharmacological therapy for glaucoma: a review. *Drugs.* **59**, 411-34.
44. **Ibelgauft H.** (2007) Epidermal growth factor/epidermaler Wachstumsfaktor <http://www.copewithcytokines.de/cope.cgi?key=EGF> cope.cgi version 5.21, revision Feb 21, 2007. (c) JI. Powered by Perl 5.006001
45. **Ibelgauft H.** (2007) <http://www.copewithcytokines.de/cope.cgi?key=IGF> insulin like growth factor/insulinartiger Wachstumsfaktor cope.cgi version 5.21, revision Feb 21, 2007. (c) JI. Powered by Perl 5.006001
46. **Imanishi J., Kamiyama K., Iguchi I., Kita M., Sotozono C., Kinoshita S.** (2000) Growth factors: importance in wound healing and maintenance of transparency of the cornea. *Prog Retin Eye Res.* **19**, 113-29.

47. **Jordan J.F.** (2003) Modulation der Wundheilung in der filtrierenden Glaukomchirurgie *Ophthalmologe*. **100**, 340-58
48. **Kathir K.M., Kumar T.K., Yu C.** (2006) Understanding the mechanism of the antimitogenic activity of suramin. *Biochemistry*. **45**, 899-906.
49. **Kay E.P., Park S.Y., Ko M.K., Lee S.C.** (1998) Fibroblast growth factor 2 uses PLC-gamma1 for cell proliferation and PI3-kinase for alteration of cell shape and cell proliferation in corneal endothelial cells. *Mol Vis*. **4**:22.
50. **Khaw P.T., Sherwood M.B., MacKay S.L., Rossi M.J., Schultz G.** (1992) Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. *Arch Ophthalmol*. **110**, 1150-4.
51. **Khaw P.T., Ward S., Porter A., Grierson I., Hitchings R.A., Rice N.S.** (1992) The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. *Invest Ophthalmol Vis Sci*. **33**, 2043-52.
52. **Khaw P.T., Occleston N.L., Schultz G., Grierson I., Sherwood M.B., Larkin G.** (1994) Activation and suppression of fibroblast function. *Eye*. **8**, 188-95.
53. **Khaw P.T., Migdal C.S.** (1996) Current techniques in wound healing modulation in glaucoma surgery. *Curr Opin Ophthalmol*. **7**, 24-33.
54. **Khaw P.T., Jones E., Mireskandari K., Dahlmann A., Cambrey A.** (2004) Modulating Wound Healing After Glaucoma Surgery *Glaucoma Today*. **2**, 12-19
55. **Klenkler B., Sheardown H.** (2004) Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. *Exp Eye Res*. **79**, 677-88.
56. **Knauer C., Pfeiffer N.** (2006) Erblindung in Deutschland – heute und 2030 *Ophthalmologe*. **103**, 735-41.
57. **Knorr M., Volker M., Denk P.O., Wunderlich K., Thiel H.J.** (1997) Proliferative response of cultured human tenon's capsule fibroblasts to platelet-derived growth factor isoforms. *Graefes Arch Clin Exp Ophthalmol*. **235**, 667-71.
58. **Koliakos G.G., Schlotzer-Schrehardt U., Konstas A.G., Bufidis T., Georgiadis N., Dimitriadou A.** (2001) Transforming and insulin-like growth factors in the aqueous humour of patients with exfoliation syndrome. *Graefes Arch Clin Exp Ophthalmol*. **239**, 482-7.
59. **Kottler U.B., Junemann A.G., Aigner T., Zenkel M., Rummelt C., Schlotzer-Schrehardt U.** (2005) Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. *Exp Eye Res*. **80**, 121-34.

- 60. Krott R., Lebek J., Grisanti S., Esser P., Heimann K.** (2000) Antiproliferative Wirkung von Genistein auf kultivierte retinale Pigmentepithelzellen vom Schwein. *Ophthalmologica*. **214**, 296-300.
- 61. Kucich U., Rosenbloom J.C., Shen G., Abrams W.R., Hamilton A.D., Sebti S.M., Rosenbloom J.** (2000) TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. *Arch Biochem Biophys*. **374**, 313-24.
- 62. Labbe A., Dupas B., Hamard P., Baudouin C.** (2004) An evaluation of blebs after filtering surgery with the in vivo confocal microscope] *J Fr Ophtalmol*. **27**, 1083-9.
- 63. Lama P.J., Fechtner R.D.** (2003) Antifibrotics and wound healing in glaucoma surgery. *Surv Ophthalmol*. **48**, 314-46.
- 64. Leschey K.H., Hines J., Singer J.H., Hackett S.F., Campochiaro P.A.** (1991) Inhibition of Growth Factor Effects in Retinal Pigment Epithelial Cells. *Invest Ophthalmol Vis Sci*. **32**, 1770-78.
- 65. Leung C.K., Yick D.W., Kwong Y.Y., Li F.C., Leung D.Y., Mohamed S., Tham C.C., Chung-chai C., Lam D.S.** (2007) Analysis of bleb morphology after trabeculectomy with Visante anterior segment optical coherence tomography. *Br J Ophthalmol*. **91**, 340-4.
- 66. Litin B.S., Jones M.A., Herschler J.** (1985) Aqueous humor-stimulated protein biosynthesis in ocular tissue fibroblast culture. *Exp Eye Res*. **41**, 183-9.
- 67. Maltseva O., Folger P., Zekaria D., Petridou S., Masur S.K.** (2001) Fibroblast growth factor reversal of the corneal myofibroblast phenotype. *Invest Ophthalmol Vis Sci*. **42**, 2490-5.
- 68. Manetti F., Corelli F., Botta M.** (2000) Fibroblast growth factors and their inhibitors. *Curr Pharm Des*. **6**, 1897-924.
- 69. Matsumoto Y., Dogru M., Goto E., Ohashi Y., Kojima T., Ishida R., Tsubota K.** (2004) Autologous serum application in the treatment of neurotrophic keratopathy. *Ophthalmology*. **111**, 1115-20.
- 70. Mead A.L., Wong T.T., Cordeiro M.F., Anderson I.K., Khaw P.T.** (2003) Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. *Invest Ophthalmol Vis Sci*. **44**, 3394-401.
- 71. Messmer E.M., Zapp D.M., Mackert M.J., Thiel M., Kampik A.** (2006) In vivo confocal microscopy of filtering blebs after trabeculectomy. *Arch Ophthalmol*. **124**, 1095-103.
- 72. Meyer-Ter-Vehn T., Gebhardt S., Sebald W., Buttman M., Grehn F., Schlunck G., Knaus P.** (2006) p38 inhibitors prevent TGF-beta-induced myofibroblast

transdifferentiation in human tenon fibroblasts. *Invest Ophthalmol Vis Sci.* **47**, 1500-9.

- 73. Middaugh C.R., Mach H., Burke C.J., Volkin D.B., Dabora J.M., Tsai P.K., Bruner M.W., Ryan J.A., Marfia K.E.** (1992) Nature of the interaction of growth factors with suramin. *Biochemistry.* **31**, 9016-24.
- 74. Mietz H., Chevez-Barrios P., Lieberman M.W., Wendt M., Gross R., Basinger S.F.** (1997) Decorin and suramin inhibit ocular fibroblast collagen production. *Graefes Arch Clin Exp Ophthalmol.* **235**, 399-403.
- 75. Mietz H., Chevez-Barrios P., Feldman R.M., Lieberman M.W.** (1998) Suramin inhibits wound healing following filtering procedures for glaucoma. *Br J Ophthalmol.* **82**, 816-20.
- 76. Mietz H., Krieglstein G.K.** (2001) Suramin to enhance glaucoma filtering procedures: a clinical comparison with mitomycin. *Ophthalmic Surg Lasers.* **32**, 358-69.
- 77. Migdal C., Gregory W., Hitchings R.** (1994) Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. *Ophthalmology.* **101**, 1651-6
- 78. Moulin V., Auger F.A., O'Connor-McCourt M., Germain L.** (1997) Fetal and postnatal sera differentially modulate human dermal fibroblast phenotypic and functional features in vitro. *J Cell Physiol.* **171**, 1-10
- 79. Munaron L.** (2002) Calcium signalling and control of cell proliferation by tyrosine kinase receptors (review). *Int J Mol Med.* **10**, 671-6.
- 80. Munaron L., Fiorio Pla A.** (2000) Calcium influx induced by activation of tyrosine kinase receptors in cultured bovine aortic endothelial cells. *J Cell Physiol.* **185**, 454-63.
- 81. Mutsch Y.A., Grehn F.** (2000) Success criteria and success rates in trabeculectomy with and without intraoperative antimetabolites using intensified postoperative care (IPC). *Graefes Arch Clin Exp Ophthalmol.* **238**, 884-91.
- 82. Occleston N.L., Daniels J.T., Tarnuzzer R.W., Sethi K.K., Alexander R.A., Bhattacharya S.S., Schultz G.S., Khaw P.T.** (1997) Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. *Invest Ophthalmol Vis Sci.* **38**, 1998-2007.
- 83. Ophir A., Ticho U.** (1992) Toxic effects of 5-fluorouracil on fibroblasts following trabeculectomy. *Ophthalmic Res.* **24**, 298-302.
- 84. Papazisis K.T., Kalemi T.G., Zambouli D., Geromichalos G.D., Lambropoulos A.F., Kotsis A., Boutis L.L., Kortsaris A.H.** (2006) Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. *Cancer Lett.* **233**, 255-64.

- 85. Pelletier D.B., Boynton A.L.** (1994) Dissociation of PDGF receptor tyrosine kinase activity from PDGF-mediated inhibition of gap junctional communication. *J Cell Physiol.* **158**, 427-34.
- 86. Pfeiffer N.** (1998) Moderne medikamentöse Glaukomtherapie *Deutsches Ärzteblatt* **95**, 3292-3297.
- 87. Picht G., Mutsch Y., Grehn F.** (2001) Nachbetreuung von Trabekulektomien - Komplikationen und therapeutische Konsequenzen. *Ophthalmologe.* **98**, 629-34.
- 88. Porter R.A., Brown R.A., Eastwood M., Occleston N.L., Khaw P.T.** (1998) Ultrastructural changes during contraction of collagen lattices by ocular fibroblasts. *Wound Repair Regen.* **6**, 157-66.
- 89. Quigley H.A.** (1996) Number of people with glaucoma worldwide. *Br J Ophthalmol.* **80**, 389-93.
- 90. Quigley H.A., Broman A.T.** (2006) The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol.* **90**, 262-7.
- 91. Raj P.A., Marcus E., Rein R.** (1998) Conformational requirements of suramin to target angiogenic growth factors. *Angiogenesis.* **2**, 183-99.
- 92. Read L.C., Ballard F.J., Francis G.L., Baxter R.C., Bagley C.J., Wallace J.C.** (1986) Comparative binding of bovine, human and rat insulin-like growth factors to membrane receptors and to antibodies against human insulin-like growth factor-1. *Biochem J.* **233**, 215-21.
- 93. Rendu F., Brohard-Bohn B.** (2001) The platelet release reaction: granules' constituents, secretion and functions. *Platelets.* **12**, 261-73
- 94. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., Mariotti S.P.** (2004) Global data on visual impairment in the year 2002. *Bull World Health Organ.* **82**, 844-51.
- 95. Rieck P.W., Kriegsch J., Jaeckel C., Hartmann C.** (2004) Effekt von Suramin auf Proliferation und Migration von Linsenepithelzellen in vitro *Ophthalmologe.* **101**, 73-9.
- 96. Saika S.** (2006) TGFbeta pathobiology in the eye. *Lab Invest.* **86**, 106-15.
- 97. Salas-Prato M., Assalian A., Mehdi A.Z., Duperre J., Thompson P., Brazeau P.** (1996) Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro. *J Glaucoma.* **5**, 54-9.
- 98. Salgado R., Vermeulen P.B., Benoy I., Weytjens R., Huget P., Van Marck E., Dirix L.Y.** (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. *Br J Cancer.* **80**, 892-7.



99. **Schwartz K., Budenz D.** (2004) Current management of glaucoma. *Curr Opin Ophthalmol.* **15**, 119-26
100. **Shah N.N., Bowd C., Medeiros F.A., Weinreb R.N., Sample P.A., Hoffmann E.M., Zangwill L.M.** (2006) Combining structural and functional testing for detection of glaucoma. *Ophthalmology.* **113**, 1593-602.
101. **Shimizu T., Kinugawa K., Yao A., Sugishita Y., Sugishita K., Harada K., Matsui H., Kohmoto O., Serizawa T., Takahashi T.** (1999) Platelet-derived growth factor induces cellular growth in cultured chick ventricular myocytes. *Cardiovasc Res.* **41**, 641-53.
102. **Siriwardena D., Edmunds B., Wormald R.P., Khaw P.T.** (2004) National survey of antimetabolite use in glaucoma surgery in the United Kingdom. *Br J Ophthalmol.* **88**, 873-6.
103. **Stein C.A., LaRocca R.V., Thomas R., McAtee N., Myers C.E.** (1989) Suramin: an anticancer drug with a unique mechanism of action. *J Clin Oncol.* **7**, 499-508.
104. **Takano S., Gately S., Neville M.E., Herblin W.F., Gross J.L., Engelhard H., Perricone M., Eidsvoog K., Brem S.** (1994) Suramin, an anticancer and angiostatic agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. *Cancer Res.* **54**, 2654-60.
105. **Theelen T., Wesseling P., Keunen J.E., Klevering B.J.** (2007) A pilot study on slit lamp-adapted optical coherence tomography imaging of trabeculectomy filtering blebs. *Graefes Arch Clin Exp Ophthalmol.* **245**, 877-82.
106. **Tripathi R.C., Borisuth N.S., Tripathi B.J.** (1992) Detection, quantification, and significance of basic fibroblast growth factor in the aqueous humor of man, cat, dog and pig. *Exp Eye Res.* **54**, 447-54.
107. **Tuominen I.S., Tervo T.M., Teppo A.M., Valle T.U., Gronhagen-Riska C., Vesaluoma M.H.** (2001) Human tear fluid PDGF-BB, TNF-alpha and TGF-beta1 vs corneal haze and regeneration of corneal epithelium and subbasal nerve plexus after PRK. *Exp Eye Res.* **72**, 631-41.
108. **van Setten G.B.** (1996) Basic fibroblast growth factor in human tear fluid: detection of another growth factor. *Graefes Arch Clin Exp Ophthalmol.* **234**, 275-7.
109. **Vesaluoma M., Teppo A.M., Gronhagen-Riska C., Tervo T.** (1997) Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy. *Curr Eye Res.* **16**, 19-25.
110. **Wiederholt M., Groth J., Strauss O.** (1998) Role of protein tyrosine kinase on regulation of trabecular meshwork and ciliary muscle contractility. *Invest Ophthalmol Vis Sci.* **39**, 1012-20.

- 111. Williams L.T., Tremble P.M., Lavin M.F., Sunday M.E.** (1984) Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. *J Biol Chem.* **259**, 5287-94.
- 112. Wormald R., Wilkins M.R., Bunce C.** (2001) Postoperative 5-Fluorouracil for glaucoma surgery. *Cochrane Database of Systematic Reviews* 2001, Issue 3. Art. No.: CD001132. DOI: 10.1002/14651858.CD001132.